- Trials with a EudraCT protocol (175)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
175 result(s) found for: Oxygen concentration.
Displaying page 1 of 9.
EudraCT Number: 2016-001584-36 | Sponsor Protocol Number: 2014-03-11 | Start Date*: 2016-06-01 |
Sponsor Name:Universitetssjukhuset Örebro | ||
Full Title: Is high oxygen concentration a riskfactor for postoperative complications? A prospective, randomized, singel blinded study in elderly patients undergoing vascular surgery | ||
Medical condition: Elective vascular surgery (peripheral vascular and aortic surgery) | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003714-68 | Sponsor Protocol Number: 1744/2017 | Start Date*: 2017-11-15 | ||||||||||||||||
Sponsor Name:Medical University of Vienna | ||||||||||||||||||
Full Title: Effect of Supplemental Oxygen on Perioperative Brain Natriuretic Peptide Concentration in Cardiac Risk Patients - A prospective randomized clinical trial | ||||||||||||||||||
Medical condition: Evaluation of the effect of 80% versus 30% supplemental oxygen administration during major abdominal surgery on postoperative brain natriuretic peptide concentration. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-004012-31 | Sponsor Protocol Number: RD 5130-009-07 | Start Date*: 2009-07-06 | |||||||||||
Sponsor Name:Derby Hospitals NHS Foundation Trust [...] | |||||||||||||
Full Title: The effects of improving oxygen concentration in the reduction of dialysis induced myocardial stunning – A pilot study | |||||||||||||
Medical condition: Chronic renal failure patients who are receiving haemodialysis treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004406-10 | Sponsor Protocol Number: 000 | Start Date*: 2013-10-09 |
Sponsor Name:University Hospital Hradec Kralove | ||
Full Title: The use of oxygen and hydrogen mixture for inhalation to prevent ischaemia-reperfusion injury | ||
Medical condition: The patients suffering form acute transmural myocardial infarction and treated with percutaneous transluminal coronary angioplasty will be included in the study. After the recanalisation of occlude... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004209-27 | Sponsor Protocol Number: 05/Q1606/127 | Start Date*: 2005-11-11 |
Sponsor Name:Oxford Radcliffe Hospitals NHS Trust | ||
Full Title: Effect of altering inspired oxygen concentrations on cerebral oxygenation during awake carotid surgery | ||
Medical condition: Carotid endarterectomy is an operation performed on patients with a symptomatic stenosis of the internal carotid artery. Such patients have usually presented with stroke or transient ischaemic atta... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2014-003380-38 | Sponsor Protocol Number: Oxyperform | Start Date*: 2014-09-23 | |||||||||||
Sponsor Name:R&D department, Hull and East Yorkshire Hospitals NHS Trust | |||||||||||||
Full Title: The effect of oxygen on exercise performance in chronic heart failure | |||||||||||||
Medical condition: Chronic heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000592-36 | Sponsor Protocol Number: CGRPAMS03 | Start Date*: 2023-07-10 | |||||||||||
Sponsor Name:Universitätsklinikum Essen | |||||||||||||
Full Title: Calcitonin Gene-Related Peptide Receptor Antagonists for Prevention of Acute Mountain Sickness | |||||||||||||
Medical condition: Acute Mountain Sickness (AMS) is a constellation of symptoms (headache, anorexia, nausea, vomiting, lightheadedness, and fatigue) occuring in unacclimatized mountaineers ascending too fast, too high | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-006174-97 | Sponsor Protocol Number: BST22006 | Start Date*: 2007-05-02 |
Sponsor Name:University of Oxford, Research Governance & Clinical Trials Office | ||
Full Title: Which oxygen saturation level should we use for very premature infants? A randomised controlled trial (BOOST-II UK) | ||
Medical condition: Respiratory distress of newborn ICD codes P22.0, P22.8, P22.9 | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) IE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-001768-27 | Sponsor Protocol Number: P20/07 | Start Date*: 2020-04-27 | |||||||||||
Sponsor Name:CH Versailles | |||||||||||||
Full Title: "STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE" GERONIMO 19 | |||||||||||||
Medical condition: Patients aged 75 years and older with confirmed infection Covid19 and saturation SaO2≤ under 95% O2> 5 L / min disqualified from a care in the ICU | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003093-32 | Sponsor Protocol Number: RC25/13 | Start Date*: 2016-06-15 | |||||||||||
Sponsor Name:IRCCS Burlo Garofolo | |||||||||||||
Full Title: Randomized controlled trial to evaluate the efficacy of high flow versus low flow oxygen therapy in bronchiolitis | |||||||||||||
Medical condition: Bronchiolitis | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002567-57 | Sponsor Protocol Number: 1.0 | Start Date*: 2020-11-23 | |||||||||||
Sponsor Name:University of Oxford / Clinical Trials and Research Governance | |||||||||||||
Full Title: To determine whether administration of almitrine bismesylate can ameliorate hypoxaemia in Covid-19 and augment effectiveness of supplementary oxygen therapy and respiratory support | |||||||||||||
Medical condition: Covid-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005247-78 | Sponsor Protocol Number: OB003 | Start Date*: 2022-01-19 | |||||||||||
Sponsor Name:Oxygen Biotech s.r.o. | |||||||||||||
Full Title: A 2-Part, Open-label, Non-randomized (Part A) and Randomized, Double-blinded, Placebo-controlled (Part B) multicentric, international study with adaptive design to evaluate safety and tolerability ... | |||||||||||||
Medical condition: COVID-19 patients suffering from moderate to severe pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002200-12 | Sponsor Protocol Number: ANN-002 | Start Date*: 2021-12-23 |
Sponsor Name:MUMC AZm | ||
Full Title: A multiple dosing study to demonstrate the safety, tolerability, pharmacokinetics and efficacy potential of intravenously administered ANXV (a recombinant human Annexin A5) in patients with confirm... | ||
Medical condition: moderate to severe COVID-19 pneumonia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001696-32 | Sponsor Protocol Number: GC2004 | Start Date*: 2020-05-08 | ||||||||||||||||
Sponsor Name:Instituto Grifols, S.A | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) versus SMT alo... | ||||||||||||||||||
Medical condition: Patients with Mild to Moderate Coronavirus Disease (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-018181-36 | Sponsor Protocol Number: 09117 | Start Date*: 2010-02-23 |
Sponsor Name:University of Nottingham | ||
Full Title: Nitrous Oxide and Functional Magnetic Resonance Imaging to investigate cerebral regional blood flow, cerebral metabolism and neuronal activity. | ||
Medical condition: This is part of a series of studies investigating the potential therapeutic use of low dose nitrous oxide in the treatment of cerebral vasospasm, a condition which occurs following brain injury and... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-011448-20 | Sponsor Protocol Number: 2008.11.007 | Start Date*: 2009-06-22 | |||||||||||
Sponsor Name:Dutch Diabetes Research Foundation | |||||||||||||
Full Title: Hyperoxic exercise training as an innovative therapy to improve metabolic control, endothelial dysfunction and physical fitness in deconditioned type 2 diabetes patients | |||||||||||||
Medical condition: insulin resistance, endothelial dysfunction, cardiovascular fitness, lipid metabolism and glycemic control in deconditioned non-insulin dependent type 2 diabetes patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002022-20 | Sponsor Protocol Number: NL61945.029.17 | Start Date*: 2017-07-27 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: The effect of inspiratory oxygen fraction on the ratio of partial arterial oxygen pressure and inspiratory oxygen fraction (PaO2/FiO2 ratio) in mechanically ventilated patients with and without mil... | |||||||||||||
Medical condition: We investigate the PaO2/FiO2 ratio in patients without and with mild to moderate ARDS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001500-41 | Sponsor Protocol Number: COV-AID | Start Date*: 2020-04-03 |
Sponsor Name:University Hospital Ghent | ||
Full Title: A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard ... | ||
Medical condition: COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002259-39 | Sponsor Protocol Number: TL-895-202 | Start Date*: 2020-09-23 | |||||||||||
Sponsor Name:Telios Pharma, Inc. | |||||||||||||
Full Title: A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer | |||||||||||||
Medical condition: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in patients with cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: RO (Prematurely Ended) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001645-40 | Sponsor Protocol Number: REPAVID-19 | Start Date*: 2020-05-06 | |||||||||||
Sponsor Name:DOMPé FARMACEUTICI S.P.A. | |||||||||||||
Full Title: Adaptive phase 2/3, randomized, controlled multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with COVID-19 pneumonia | |||||||||||||
Medical condition: COVID-19 pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
